Last reviewed · How we verify
SEL-212
At a glance
| Generic name | SEL-212 |
|---|---|
| Also known as | Pegadricase plus SVP-rapamycin |
| Sponsor | Selecta Biosciences, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy II (PHASE3)
- A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy (PHASE3)
- A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Participants Refractory to Conventional Therapy (PHASE2)
- Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid (PHASE2)
- Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid Levels (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SEL-212 CI brief — competitive landscape report
- SEL-212 updates RSS · CI watch RSS
- Selecta Biosciences, Inc. portfolio CI